GlaxoSmithKline, a British multinational pharmaceutical company, announced that it has sold its stake in Unilever’s Indian business for $3.35 billion. The funds will help GSK in its goal of reinvigorating its drug development pipeline, having made costly bets on experimental cancer treatments and future cell and gene therapies amid sluggish revenue growth. The 133.77 million…